CAH Stock Analysis — Cardinal Health
Sector: Healthcare Distribution
AI Verdict
Cardinal Health trades at 18.9x next year's earnings with a huge 72.4% EPS growth expectation, making it cheap for the growth on offer if its distribution moat keeps competitors at bay.
Competitive Moat
Cardinal Health operates one of the largest pharmaceutical and medical supply distribution networks in the U.S., giving it scale advantages and sticky relationships with hospitals and pharmacies. Its logistics infrastructure and long-term contracts create high switching costs for customers.
Summary
A massive jump in forward EPS growth expectations (+72.4%) is driving a sharp drop in forward P/E to 18.9x, well below its trailing multiple.
Where It Stands
CAH returned 57.19% over the past year, trades at 18.9x next year's earnings (below the healthcare sector median of 22x), and sits at a neutral RSI of 56.5.
Key Metrics
- RSI: 56.5 — Neutral
- Trailing P/E: 32.5x
- Forward P/E: 18.9x
- PEG Ratio: 0.46
- Earnings Growth: +0.7%
- Revenue Growth: +0.1%
- Market Cap: $54.7B
- Dividend Yield: 0.01%
- 1-Year Return: 57.19%
- 52-Week High: $258.30
- 52-Week Low: $145.47
Analyst Consensus
20 Buy · 3 Hold · 0 Sell (23 analysts)
Bull Case
With analysts forecasting 72.4% EPS growth and a forward P/E of 18.9x, you’re getting rapid earnings acceleration at a discount to the sector median.
Bear Case
If the forward P/E reverts to the trailing 32.5x level due to missed growth, the stock could see a 42% valuation hit even before considering price momentum cooling from a 56.5 RSI.
Catalyst to Watch
Quarterly earnings guidance updates — any sign that the 72.4% EPS growth isn’t materializing could trigger a sharp multiple reset.